Arch Biopartners Inc announced today that the U.S. Patent and Trademark Office has issued US Patent 8,530,429 protecting its peptide technology which targets brain tumour initiating cells (BTICs) and invasive glioma cells (IGCs).
The patent protects novel synthetic peptides that target and attach to human BTICs and IGCs. The issuance of this patent gives Arch protection for Arch's technology in the most important pharmaceutical market in the world. Arch anticipates similar patents will be issued in the rest of the world's major pharmaceutical markets in due course.
This patent is based on technology invented by Dr. Stephen Robbins, Dr. Donna Senger and Dr. Jennifer Rahn at the University of Calgary.